{"id":107156,"date":"2025-11-04T12:03:24","date_gmt":"2025-11-04T11:03:24","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/?p=107156"},"modified":"2025-11-04T12:47:43","modified_gmt":"2025-11-04T11:47:43","slug":"endor-technologies-obtiene-16-millones-del-cdti-para-desarrollar-un-innovador-tratamiento-contra-la-metastasis-hepatica","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/es\/endor-technologies-obtiene-16-millones-del-cdti-para-desarrollar-un-innovador-tratamiento-contra-la-metastasis-hepatica\/","title":{"rendered":"Endor Technologies obtiene 1,6 millones del CDTI para desarrollar un innovador tratamiento contra la met\u00e1stasis hep\u00e1tica"},"content":{"rendered":"<p><strong><a href=\"https:\/\/www.pcb.ub.edu\/es\/empresa\/endor-technologies\/\" target=\"_blank\" rel=\"noopener\">Endor Technologies<\/a>, una compa\u00f1\u00eda biotecnol\u00f3gica instalada en el Parque Cient\u00edfico de Barcelona (PCB-UB) y especializada en el desarrollo de soluciones innovadoras en dermocosm\u00e9tica y oncolog\u00eda, ha recibido una inversi\u00f3n de 1,6 millones de euros del Centro para el Desarrollo Tecnol\u00f3gico y la Innovaci\u00f3n (CDTI) para avanzar en un tratamiento pionero contra la met\u00e1stasis hep\u00e1tica. El ensayo cl\u00ednico de Fase II, dise\u00f1ado por la empresa, se llevar\u00e1 a cabo con la colaboraci\u00f3n del Barcelona Clinical Coordinating Center (BCCC) de la Fundaci\u00f3 Mon Cl\u00ednic Barcelona y de diversos hospitales de referencia en toda Espa\u00f1a. El objetivo m\u00e1s inmediato de Endor es alcanzar el <em>First Patient In<\/em> (FPI) en 2026, es decir, la inclusi\u00f3n del primer paciente en el ensayo.<\/strong><\/p>\n<p>La inversi\u00f3n realizada por el CDTI avala la solvencia y la calidad cient\u00edfica de la l\u00ednea de investigaci\u00f3n y permite financiar el ensayo en pacientes sin interrumpir las inversiones en las otras dos l\u00edneas de I+D de la compa\u00f1\u00eda, centradas en la dermocosm\u00e9tica y en soluciones sanitarias para la mucositis oral. Se trata de un ensayo cl\u00ednico pionero a nivel mundial para probar una terapia basada en un principio completamente distinto al de los tratamientos oncol\u00f3gicos tradicionales.<\/p>\n<p>Por primera vez, se evaluar\u00e1 una estrategia que no busca destruir los tumores, sino confinarlos, priv\u00e1ndolos de espacio para crecer y provocando as\u00ed su necrosis de forma natural. La fase inicial incluir\u00e1 entre 10 y 20 hospitales y prev\u00e9 reclutar alrededor de 100 pacientes en un programa cl\u00ednico de aproximadamente dos a\u00f1os de duraci\u00f3n.<\/p>\n<p>\u201cEste apoyo del CDTI marca un punto de inflexi\u00f3n para Endor y reconoce el esfuerzo de nuestro equipo cient\u00edfico\u201d, afirma <strong>Joaqu\u00edn Querol<\/strong>, CEO y cofundador de Endor Technologies. \u201cEstamos explorando una estrategia sin precedentes, basada en un mecanismo de acci\u00f3n nunca antes probado en humanos. Este avance representa un paso decisivo para seguir transformando la investigaci\u00f3n en ciencia aplicada con impacto real en los pacientes\u201d.<\/p>\n<p>Los pr\u00f3ximos pasos incluyen la validaci\u00f3n del protocolo cl\u00ednico para melanoma y c\u00e1ncer colorrectal con met\u00e1stasis hep\u00e1tica por parte de las agencias reguladoras, la selecci\u00f3n de los centros participantes, el inicio del proceso regulatorio del ensayo fase II, as\u00ed como el reclutamiento de los primeros pacientes y el an\u00e1lisis intermedio de seguridad y eficacia.<\/p>\n<p>La terapia objeto del estudio se basa en la administraci\u00f3n de factores de crecimiento que estimulan la m\u00e9dula \u00f3sea para inducir una respuesta estructural en el entorno tumoral. El objetivo es limitar f\u00edsicamente la expansi\u00f3n del tumor, confin\u00e1ndolo en un espacio reducido y evitando as\u00ed su progresi\u00f3n. Esta estrategia contrasta con los tratamientos oncol\u00f3gicos est\u00e1ndar, que buscan destruir las c\u00e9lulas tumorales mediante citotoxicidad, radiaci\u00f3n o inmunoterapia.<\/p>\n<p><strong>\u00bb Enlace a la noticia: <\/strong><a href=\"https:\/\/endortechnologies.com\/\" target=\"_blank\" rel=\"noopener\">web de Endor Technologies [+]<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Endor Technologies, una compa\u00f1\u00eda biotecnol\u00f3gica instalada en el Parque Cient\u00edfico de Barcelona (PCB-UB) y especializada en el desarrollo de soluciones innovadoras en dermocosm\u00e9tica y oncolog\u00eda, ha recibido una inversi\u00f3n de&#8230;<\/p>\n","protected":false},"author":14,"featured_media":107169,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[356],"tags":[360],"class_list":["post-107156","post","type-post","status-publish","format-standard","has-post-thumbnail","category-empresas","tag-endor-technologies"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Endor Technologies obtiene 1,6 millones del CDTI para desarrollar un innovador tratamiento contra la met\u00e1stasis hep\u00e1tica - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"description\" content=\"El objetivo m\u00e1s inmediato de Endor\u00a0 es alcanzar el First Patient In (FPI) en 2026, es decir, la inclusi\u00f3n del primer paciente en el ensayo.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/es\/endor-technologies-obtiene-16-millones-del-cdti-para-desarrollar-un-innovador-tratamiento-contra-la-metastasis-hepatica\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Endor Technologies obtiene 1,6 millones del CDTI para desarrollar un innovador tratamiento contra la met\u00e1stasis hep\u00e1tica - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"El objetivo m\u00e1s inmediato de Endor\u00a0 es alcanzar el First Patient In (FPI) en 2026, es decir, la inclusi\u00f3n del primer paciente en el ensayo.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/es\/endor-technologies-obtiene-16-millones-del-cdti-para-desarrollar-un-innovador-tratamiento-contra-la-metastasis-hepatica\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-04T11:03:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-04T11:47:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/11\/Adobe-Express-file-71.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"350\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Paula Ca\u00f1al\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Paula Ca\u00f1al\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/endor-technologies-obtiene-16-millones-del-cdti-para-desarrollar-un-innovador-tratamiento-contra-la-metastasis-hepatica\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/endor-technologies-obtiene-16-millones-del-cdti-para-desarrollar-un-innovador-tratamiento-contra-la-metastasis-hepatica\\\/\"},\"author\":{\"name\":\"Paula Ca\u00f1al\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"headline\":\"Endor Technologies obtiene 1,6 millones del CDTI para desarrollar un innovador tratamiento contra la met\u00e1stasis hep\u00e1tica\",\"datePublished\":\"2025-11-04T11:03:24+00:00\",\"dateModified\":\"2025-11-04T11:47:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/endor-technologies-obtiene-16-millones-del-cdti-para-desarrollar-un-innovador-tratamiento-contra-la-metastasis-hepatica\\\/\"},\"wordCount\":507,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/endor-technologies-obtiene-16-millones-del-cdti-para-desarrollar-un-innovador-tratamiento-contra-la-metastasis-hepatica\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Adobe-Express-file-71.jpg\",\"keywords\":[\"Endor Technologies\"],\"articleSection\":[\"EMPRESAS\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/endor-technologies-obtiene-16-millones-del-cdti-para-desarrollar-un-innovador-tratamiento-contra-la-metastasis-hepatica\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/endor-technologies-obtiene-16-millones-del-cdti-para-desarrollar-un-innovador-tratamiento-contra-la-metastasis-hepatica\\\/\",\"name\":\"Endor Technologies obtiene 1,6 millones del CDTI para desarrollar un innovador tratamiento contra la met\u00e1stasis hep\u00e1tica - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/endor-technologies-obtiene-16-millones-del-cdti-para-desarrollar-un-innovador-tratamiento-contra-la-metastasis-hepatica\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/endor-technologies-obtiene-16-millones-del-cdti-para-desarrollar-un-innovador-tratamiento-contra-la-metastasis-hepatica\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Adobe-Express-file-71.jpg\",\"datePublished\":\"2025-11-04T11:03:24+00:00\",\"dateModified\":\"2025-11-04T11:47:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"description\":\"El objetivo m\u00e1s inmediato de Endor\u00a0 es alcanzar el First Patient In (FPI) en 2026, es decir, la inclusi\u00f3n del primer paciente en el ensayo.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/endor-technologies-obtiene-16-millones-del-cdti-para-desarrollar-un-innovador-tratamiento-contra-la-metastasis-hepatica\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/endor-technologies-obtiene-16-millones-del-cdti-para-desarrollar-un-innovador-tratamiento-contra-la-metastasis-hepatica\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/endor-technologies-obtiene-16-millones-del-cdti-para-desarrollar-un-innovador-tratamiento-contra-la-metastasis-hepatica\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Adobe-Express-file-71.jpg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Adobe-Express-file-71.jpg\",\"width\":900,\"height\":350},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/endor-technologies-obtiene-16-millones-del-cdti-para-desarrollar-un-innovador-tratamiento-contra-la-metastasis-hepatica\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Endor Technologies obtiene 1,6 millones del CDTI para desarrollar un innovador tratamiento contra la met\u00e1stasis hep\u00e1tica\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\",\"name\":\"Paula Ca\u00f1al\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"caption\":\"Paula Ca\u00f1al\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/author\\\/paula\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Endor Technologies obtiene 1,6 millones del CDTI para desarrollar un innovador tratamiento contra la met\u00e1stasis hep\u00e1tica - Parc Cient\u00edfic de Barcelona","description":"El objetivo m\u00e1s inmediato de Endor\u00a0 es alcanzar el First Patient In (FPI) en 2026, es decir, la inclusi\u00f3n del primer paciente en el ensayo.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/es\/endor-technologies-obtiene-16-millones-del-cdti-para-desarrollar-un-innovador-tratamiento-contra-la-metastasis-hepatica\/","og_locale":"es_ES","og_type":"article","og_title":"Endor Technologies obtiene 1,6 millones del CDTI para desarrollar un innovador tratamiento contra la met\u00e1stasis hep\u00e1tica - Parc Cient\u00edfic de Barcelona","og_description":"El objetivo m\u00e1s inmediato de Endor\u00a0 es alcanzar el First Patient In (FPI) en 2026, es decir, la inclusi\u00f3n del primer paciente en el ensayo.","og_url":"https:\/\/www.pcb.ub.edu\/es\/endor-technologies-obtiene-16-millones-del-cdti-para-desarrollar-un-innovador-tratamiento-contra-la-metastasis-hepatica\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2025-11-04T11:03:24+00:00","article_modified_time":"2025-11-04T11:47:43+00:00","og_image":[{"width":900,"height":350,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/11\/Adobe-Express-file-71.jpg","type":"image\/jpeg"}],"author":"Paula Ca\u00f1al","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Paula Ca\u00f1al","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/es\/endor-technologies-obtiene-16-millones-del-cdti-para-desarrollar-un-innovador-tratamiento-contra-la-metastasis-hepatica\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/endor-technologies-obtiene-16-millones-del-cdti-para-desarrollar-un-innovador-tratamiento-contra-la-metastasis-hepatica\/"},"author":{"name":"Paula Ca\u00f1al","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"headline":"Endor Technologies obtiene 1,6 millones del CDTI para desarrollar un innovador tratamiento contra la met\u00e1stasis hep\u00e1tica","datePublished":"2025-11-04T11:03:24+00:00","dateModified":"2025-11-04T11:47:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/es\/endor-technologies-obtiene-16-millones-del-cdti-para-desarrollar-un-innovador-tratamiento-contra-la-metastasis-hepatica\/"},"wordCount":507,"image":{"@id":"https:\/\/www.pcb.ub.edu\/es\/endor-technologies-obtiene-16-millones-del-cdti-para-desarrollar-un-innovador-tratamiento-contra-la-metastasis-hepatica\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/11\/Adobe-Express-file-71.jpg","keywords":["Endor Technologies"],"articleSection":["EMPRESAS"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/es\/endor-technologies-obtiene-16-millones-del-cdti-para-desarrollar-un-innovador-tratamiento-contra-la-metastasis-hepatica\/","url":"https:\/\/www.pcb.ub.edu\/es\/endor-technologies-obtiene-16-millones-del-cdti-para-desarrollar-un-innovador-tratamiento-contra-la-metastasis-hepatica\/","name":"Endor Technologies obtiene 1,6 millones del CDTI para desarrollar un innovador tratamiento contra la met\u00e1stasis hep\u00e1tica - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/es\/endor-technologies-obtiene-16-millones-del-cdti-para-desarrollar-un-innovador-tratamiento-contra-la-metastasis-hepatica\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/es\/endor-technologies-obtiene-16-millones-del-cdti-para-desarrollar-un-innovador-tratamiento-contra-la-metastasis-hepatica\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/11\/Adobe-Express-file-71.jpg","datePublished":"2025-11-04T11:03:24+00:00","dateModified":"2025-11-04T11:47:43+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"description":"El objetivo m\u00e1s inmediato de Endor\u00a0 es alcanzar el First Patient In (FPI) en 2026, es decir, la inclusi\u00f3n del primer paciente en el ensayo.","breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/es\/endor-technologies-obtiene-16-millones-del-cdti-para-desarrollar-un-innovador-tratamiento-contra-la-metastasis-hepatica\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/es\/endor-technologies-obtiene-16-millones-del-cdti-para-desarrollar-un-innovador-tratamiento-contra-la-metastasis-hepatica\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.pcb.ub.edu\/es\/endor-technologies-obtiene-16-millones-del-cdti-para-desarrollar-un-innovador-tratamiento-contra-la-metastasis-hepatica\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/11\/Adobe-Express-file-71.jpg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/11\/Adobe-Express-file-71.jpg","width":900,"height":350},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/es\/endor-technologies-obtiene-16-millones-del-cdti-para-desarrollar-un-innovador-tratamiento-contra-la-metastasis-hepatica\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/es\/"},{"@type":"ListItem","position":2,"name":"Endor Technologies obtiene 1,6 millones del CDTI para desarrollar un innovador tratamiento contra la met\u00e1stasis hep\u00e1tica"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a","name":"Paula Ca\u00f1al","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","caption":"Paula Ca\u00f1al"},"url":"https:\/\/www.pcb.ub.edu\/es\/author\/paula\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/107156","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/comments?post=107156"}],"version-history":[{"count":2,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/107156\/revisions"}],"predecessor-version":[{"id":107163,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/107156\/revisions\/107163"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media\/107169"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media?parent=107156"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/categories?post=107156"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/tags?post=107156"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}